Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly's Kisunla (donanemab) has received marketing authorization in Australia for treating early symptomatic Alzheimer's disease in adults who are ApoE ε4 heterozygotes or non-carriers. This marks the 13th regulatory authorization globally for the drug.
Key clinical results from the TRAILBLAZER-ALZ 2 Phase 3 study showed that Kisunla:
- Slowed cognitive and functional decline by up to 35% compared to placebo at 18 months
- Reduced disease progression risk by 39% over the same period
The drug targets amyloid plaques and is notable as the only amyloid-targeting therapy with evidence supporting treatment discontinuation once plaques are removed. Of the estimated 600,000 Australians living with Alzheimer's, approximately 450,000 in early stages could be assessed for Kisunla treatment eligibility.
Eli Lilly (NYSE: LLY) announced plans to invest up to $250 million in an expanded collaboration with Purdue University over the next eight years, potentially becoming the largest industry-academic agreement in U.S. history. The Lilly-Purdue 360 Initiative, extending through 2032, aims to accelerate pharmaceutical innovation across the entire pipeline.
The partnership will focus on key areas including: AI-powered drug discovery, technology-enabled treatment acceleration, manufacturing optimization through robotics and AI, and workforce development. The collaboration includes on-site research opportunities at both institutions and builds on existing programs like Lilly Scholars and the Lilly and Purdue Research Alliance Center (LPRC).
Eli Lilly (NYSE: LLY) announced key executive leadership changes to support its continued growth trajectory. Ilya Yuffa, currently EVP and president of Lilly International, will become EVP and president of Lilly USA and Global Customer Capabilities, leading U.S. operations and product launches. Patrik Jonsson, current EVP and president of Lilly Cardiometabolic Health and Lilly USA, will transition to EVP and president of Lilly International, overseeing all non-U.S. markets. Kenneth Custer, Ph.D., currently GM of Lilly Canada, will be promoted to EVP and president of Lilly Cardiometabolic Health and join the executive committee. These changes aim to enhance the company's focus on U.S. business and global therapeutic areas amid significant growth in cardiometabolic health and U.S. operations.